From: A multi-site feasibility study for personalized medicine in canines with Osteosarcoma
Inclusion criteria | Exclusion criteria |
---|---|
Client-owned pet dogs ≥ 1 year of age, any gender and weight. | Anticipated poor owner compliance. |
Informed owner consent prior to enrollment screening. | Pregnant or likely to become pregnant. |
Suspected diagnosis of primary appendicular OSA (+/− metastasis) via radiographs and physical exam or confirmed diagnosis based cytology or histopathology of the affected limb. | Receiving/have received treatment for cancer including chemotherapy, bisphosphonate therapy, prednisone therapy, radiation therapy or immunotherapy, other than Non-steroidal Anti-inflammatory Drugs (NSAIDS). |
Any disease stage. | Previously amputated limb as a result of OSA. |
Naïve (i.e. de novo) cases. | Concurrent malignancy that is non-appendicular OSA. |
Planned amputation. | Primary cancer originated at an anatomical sites other than appendicular OSA. |
 | Other serious systemic disorder incompatible with this study. |
 | Acupuncture treatment less than 2 weeks prior to sample collection day (dogs that have commenced acupuncture > 2 weeks prior to Day 0 can be included but they must stay on their acupuncture treatment during the study period). |
 | Dogs that are participating in another clinical trial, (subjects are allowed to enroll on a trial after the samples have been collected). |
 | Quality Control (QC) failure (histopathological or genomic). |